Leerink analyst Faisal Khurshid downgraded Pliant Therapeutics (PLRX) to Market Perform from Outperform with a price target of $2, down from $33. The company announced the discontinuation of its Phase 2b/3 trial evaluating bexotegrast in idiopathic pulmonary fibrosis due to an imbalance in adverse events between treatment and placebo, the analyst tells investors in a research note. The firm cites the current lack of clarity on the path forward for the downgrade. The stock in midday trading is down 52%, or $1.78, to $1.67.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLRX:
- Pliant Therapeutics downgraded to Market Perform from Outperform at Leerink
- Pliant Therapeutics price target lowered to $17 from $40 at Piper Sandler
- Pliant Therapeutics discontinues BEACON-IPF Phase 2b trial of bexotegrast
- Pliant Therapeutics, Inc. (PLRX) Q4 Earnings Cheat Sheet
- Positive Outlook on Pliant Therapeutics Despite Trial Uncertainty